COVID-19 Clinical Trials in Houston

Showing 161-180 of 201 trials

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

NCT04414618

This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive matching placebo in addition to standard of care unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.

Coronavirus Infections

RedHill Biopharma Limited42 participantsStarted Jul 2020

Scottsdale, Arizona, United States • Miami, Florida, United States • Detroit, Michigan, United States +6 more locations

UNKNOWNPhase 1/2< 1 mile

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340

This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19.

COVID-19Acute Respiratory Distress SyndromeSARS-CoV-2+1 more

Reven Pharmaceuticals, Inc.237 participantsStarted Mar 2021

Houston, Texas, United States • Houston, Texas, United States • New Braunfels, Texas, United States

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Tolerability and Efficacy of RJX in Patients With COVID-19

COVID-19 Trials in Other Cities

Adaptive COVID-19 Treatment Trial (ACTT)

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study

Expanded Access Remdesivir (RDV; GS-5734™)

COVID-19 Progression in End-Stage Kidney Disease

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

Other Conditions in Houston